JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Details
By J. Smith
J. Smith
Articles
Last Updated: 29 June 2025
Hits: 332
  • Type 2 Diabetes
  • Metabolic Health
  • mRNA Vaccines
  • Vaccine Safety
  • mRNA Medicine

Why mRNAs Are a Good Option for Vaccines

mRNA molecular strain. Courtesy of Moderna.

A plain-language guide to how mRNA works and why it matters for future health care

Abstract

mRNA vaccines work by delivering temporary instructions that help the body produce a harmless protein and build immune protection—without using live viruses or altering DNA. Backed by decades of research, this approach offers a safe, flexible alternative to traditional vaccines. Clear explanations dispel common misconceptions and highlight how mRNA technology could one day support treatments for chronic conditions like type 2 diabetes.

Key Points

  • mRNA is a natural process your body uses every day to make proteins; mRNA vaccines simply provide instructions to produce one harmless protein to trigger immune protection.
  • mRNA cannot alter DNA or cause infection — it never enters the cell nucleus and breaks down shortly after delivering its message.
  • Lipid nanoparticles (LNPs) protect fragile mRNA and help it enter cells safely, allowing for effective delivery without long-term presence in the body.
  • The platform behind mRNA vaccines was built on decades of research, enabling rapid, flexible responses to health threats — including potential future use in metabolic disorders.
  • Clear communication and fact-based explanations are essential to combat misinformation and help people make informed decisions about mRNA technology.

Read more: Why mRNAs Are a Good Option for Vaccines

Details
By J. Smith
J. Smith
Articles
Last Updated: 31 May 2025
Hits: 127
  • Type 2 Diabetes
  • Obesity Care
  • Health Literacy
  • Understanding Clinical Data
  • CGM Data

Why I Took Medical Courses to Strengthen My Data Skills

Abstract

This post explains why I took medical courses to gain a deeper understanding of the clinical side of type 2 diabetes and obesity care. The insights gained help me better interpret the data, support public education, and present CGM and related metrics in a more informed way.

Key Points

  • Medical coursework offered critical insight into diabetes and obesity care priorities.
  • Understanding clinical perspectives shaped how I interpret CGM data.
  • CME courses emphasized scientific integrity and commercial neutrality.
  • These experiences support better health communication and patient education.
  • Learning from clinicians strengthens how I present data to the public.

Read more: Why I Took Medical Courses to Strengthen My Data Skills

Details
By J. Smith
J. Smith
Articles
Last Updated: 28 May 2025
Hits: 266
  • Type 2 Diabetes
  • Blood Sugar Control
  • Personalized Medicine
  • Insulin Sensitivity
  • Muscle Health

New Research Reveals the Hidden Complexity of Insulin Resistance

Left to right: Executive Director Professor Juleen R. Zierath, Associate Professor Atul S. Deshmukh, Executive Director Professor Kei Sakamoto, and Professor Simon Rasmussen. Courtesy of the Novo Nordisk Foundation Center for Basic Metabolic Research

Abstract

A new study led by researchers at the University of Copenhagen and Karolinska Institutet reveals that insulin resistance varies widely between individuals, even among those with the same diagnosis. By analyzing muscle tissue from over 120 people, the team uncovered unique molecular "fingerprints" that could help detect insulin resistance earlier and guide more personalized treatments for type 2 diabetes. Professor Juleen Zierath, a pioneer in exercise and metabolic research and winner of the 2024 Diabetes Prize for Excellence, played a key role in the study. The findings highlight the importance of moving beyond one-size-fits-all approaches in diabetes care.

Key Points

  • Researchers discovered unique molecular “fingerprints” in muscle that reveal how individuals respond to insulin.
  • Insulin resistance varies widely, even among people with the same diagnosis.
  • Some individuals with type 2 diabetes respond better to insulin than those without the condition.
  • A human-specific muscle protein, AMPKγ3, may offer a new target for treatment.
  • The findings support more personalized and earlier approaches to diabetes care.

Read more: New Research Reveals the Hidden Complexity of Insulin Resistance

Details
By J. Smith
J. Smith
Articles
Last Updated: 20 May 2025
Hits: 259
  • Continuous Glucose Monitoring
  • 2025 Diabetes Guidelines
  • ADA Standards of Care
  • Personalized Diabetes Care
  • Diabetes Education

What the 2025 Diabetes Care Updates Mean for You

2025 Standards of Care. Image courtesy of American Diabetes Association (ADA).

Abstract

The American Diabetes Association’s 2025 Standards of Care reflect a growing shift toward personalized, patient-centered diabetes management. This overview translates key updates for individuals living with diabetes, emphasizing broader use of technology, smarter lifestyle guidance, integration of heart and kidney care, and increased attention to social and environmental factors. The focus is no longer just on medications, but on the full context of a person’s health and daily life.

The American Diabetes Association (ADA) released its updated Standards of Care in Diabetes for 2025 several months ago. These annual updates guide how healthcare providers deliver diabetes care across the U.S. While the standards are written for clinicians, many of the changes have a direct impact on people living with diabetes. This summary highlights what’s new and why it matters from a patient perspective.

Key Points

  • More personalized care plans – New guidelines support tailoring diabetes treatment based on individual needs, not just type 1 or type 2 labels.
  • Broader access to CGM technology – Continuous glucose monitors are now recommended for more people, including some with type 2 diabetes not on insulin.
  • Lifestyle advice goes beyond diet and exercise – Sleep quality, muscle maintenance, and hydration are emphasized alongside plant-based nutrition.
  • Support beyond medication – Social factors like affordability and access to care are now officially part of diabetes treatment planning.
  • Integrated heart, kidney, and liver care – Screening and treatment are becoming more coordinated to protect long-term health.

Read more: What the 2025 Diabetes Care Updates Mean for You

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

Page 2 of 22

Articles

  • The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity
  • Sustained Weight Loss and Cardiovascular Risk Reduction with Wegovy
  • Subtle Yet Significant Changes: The 2024 ADA Standards of Care in Diabetes
  • What the 2025 Diabetes Care Updates Mean for You
  • FDA Issues Alert on Compounded Semaglutide Dosing Errors
  • FDA's Decision on Yogurt and Type 2 Diabetes Risk Reduction
  • Why I Took Medical Courses to Strengthen My Data Skills
  • Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
  • Viewing Type 2 Diabetes as a Vascular Disease
  • How Well Do My CGM and BGM Readings Match?
  • Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
  • Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
  • Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
  • Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • The Future of Type 2 Diabetes and Obesity Care: The Role of DNA Sequencing
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • Wegovy: A New Horizon in Cardiovascular Risk Reduction for Obesity
  • GLP-1 RAs and Gastroparesis (Stomach Paralysis)
  • Studies of Cinnamon for Blood Sugar Control: Mixed Results with No Clear Answer
  • Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity

News

October 2025

  • FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
  • Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
  • Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
  • Semaglutide’s Heart Benefits Extend Beyond Weight Loss
  • Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

  • CVS Caremark Faces Lawsuit Over Dropping Zepbound
  • Dexcom Introduces Smart Basal at EASD 2025
  • Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
  • Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
  • Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
  • Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
  • Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

  • FDA Approves Wegovy for MASH Treatment
  • FDA Expands Repatha Access to More High-Risk Adults
  • Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
  • Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
  • Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
  • Signos Press Release Raises Questions About FDA Clearance Claims
  • Teva Launches First Generic GLP-1 for Obesity
  • Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Semaglutide
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • Diabetes
  • Obesity
  • FDA Approval
  • Diabetes Management
  • Cardiovascular Health
  • Mounjaro
  • SELECT Trial
  • Continuous Glucose Monitoring
  • GLP-1 Therapy
  • Obesity Management
  • Metabolic Health
  • Orforglipron
  • Disease Modification
  • Dexcom
  • CGM
  • Rybelsus
  • Clinical Trials
  • Oral Semaglutide
  • FDA
  • Diabetes Treatment

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
 
Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.